| COVID-19 Vaccine |
1 |
1 |
| Vaccines |
0 |
0.92 |
| Rheumatic Disease |
0 |
0.99 |
| COVID-19 |
0 |
0.56 |
| Patient Safety |
0 |
0.55 |
| Child |
0 |
0.98 |
| Biologic Therapy |
0 |
0.48 |
| Adolescent Medicine |
0 |
0.97 |
| Immunization |
0 |
0.35 |
| Pain Management |
0 |
0.35 |
| Adverse Effects |
0 |
0.26 |
| Obesity |
0 |
0.26 |
| Antineoplastic Drug |
0 |
0.17 |
| Hospital |
0 |
0.17 |
| Monoclonal Antibody |
0 |
0.17 |
| Acute Respiratory Distress Syndrome |
0 |
0.15 |
| Arthralgia |
0 |
0.15 |
| Systemic Lupus Erythematosus |
0 |
0.15 |
| Arthritis |
0 |
0.13 |
| Fever |
0 |
0.13 |
| Pain |
0 |
0.13 |
| Uveitis |
0 |
0.12 |
| Vasculitis |
0 |
0.1 |
| Immunoglobulin G (IgG) |
0 |
0.09 |
| Immunoglobulin G (IgG) Serum |
0 |
0.09 |
| Indiana |
0 |
0.09 |
| Juvenile Rheumatoid Arthritis (JRA) |
0 |
0.09 |
| Lupus |
0 |
0.09 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.09 |
| Young Adult |
0 |
0.09 |
| Scleroderma |
0 |
0.07 |
| Renal Failure |
0 |
0.06 |
| Asthma |
0 |
0.05 |
| Chronic Kidney Disease |
0 |
0.05 |
| Auto-inflammatory Diseases |
0 |
0.04 |
| C-Reactive Protein (CRP) |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Dehydration |
0 |
0.04 |
| Dermatomyositis |
0 |
0.04 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.04 |
| Diversity |
0 |
0.04 |
| Glucocorticoid |
0 |
0.04 |
| Granulomatosis |
0 |
0.04 |
| Hemorrhage |
0 |
0.04 |
| Immunosuppressive Therapy |
0 |
0.04 |
| Lung |
0 |
0.04 |
| Muscle |
0 |
0.04 |
| Pennsylvania |
0 |
0.04 |
| Severe Acute Respiratory Syndrome |
0 |
0.04 |
| Steroids |
0 |
0.04 |
| Systemic Sclerosis |
0 |
0.04 |
| Tumor |
0 |
0.04 |
| Weakness |
0 |
0.04 |
| Cardiovascular Risk Management |
0 |
0.03 |
| Headache |
0 |
0.03 |
| Inflammatory Bowel Disease |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |